Saudi-Born Startup Kilow Launches Arabic-Language Weight Loss App
Saudi health tech startup Kilow has officially launched its Arabic-language platform, offering a personalised, all-in-one digital weight loss solution tailored to local lifestyles. The app, now available across Saudi Arabia, merges smart health tracking, expert-led lifestyle coaching, and access to licensed medical care—including GLP-1-based weight loss medication, when appropriate.
Kilow was founded by Fahed Al Essa, a four-time startup founder and digital health expert whose background spans biotech, public health, and clinical operations. Developed entirely in Saudi Arabia, the app is designed to reflect the specific habits, food cultures, and behavioural patterns of users in the Kingdom.
'This isn't just another weight loss app,' says Al Essa. 'It's built by people who understand the Saudi lifestyle and the health challenges we face. For me, Kilow is deeply personal—after years of struggling with my weight, I finally feel like I've found a solution that works, and I wanted to share that with others.'
Users begin with a brief onboarding process and receive a free medical consultation. Approved participants can select flexible plans ranging from one to six months, with options that include home-delivered medication, lab testing kits, and ongoing tracking of nutrition, movement, and sleep.
Beyond standard diet coaching, Kilow is grounded in science-backed, culturally relevant interventions. 'If you tell someone in the GCC to stop eating rice, they probably won't. But if you teach them how to eat rice better, that's where we specialize,' Al Essa adds. 'We don't want to overhaul your life. We give you small, practical tools—like having vinegar before your rice meal to reduce blood sugar spikes. Tiny changes. Big effect.'
The launch comes at a time when Saudi Arabia is increasingly prioritising wellness and preventative care as part of Vision 2030. Kilow plans to expand regionally and is preparing to raise its first funding round in the coming weeks.
Future features include AI-powered meal feedback, wearable integrations, and adaptive coaching tools based on biometric data. The company is also working on precision health modules that will incorporate genetic testing, hormonal profiling, and predictive health scoring to flag plateau phases before they occur.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
See - Sada Elbalad
4 hours ago
- See - Sada Elbalad
NASA, Google Create AI Doctor for Space
Israa Farhan NASA and Google are jointly testing a new artificial intelligence-powered medical assistant designed to support astronauts during long-duration missions to the Moon and Mars. According to the project aims to help astronauts diagnose and treat medical issues in deep space, where immediate consultations with Earth-based doctors are impossible and returning home is not an option. As part of its Artemis program, NASA is working with Google to trial a prototype called the Crew Medical Officer Digital Assistant (CMODI). The AI-driven system is designed to analyze symptoms, previous diagnoses, and test results before suggesting possible treatments or diagnostic options. The technology would give astronauts the ability to independently manage health challenges beyond low-Earth orbit, ensuring they can address medical concerns during lunar or Martian expeditions without relying on delayed communications with doctors on Earth. highlighted that this digital health assistant could also prove invaluable on Earth, especially in remote or hard-to-reach regions where medical professionals are scarce. read more UAE's Lunar Mission Delayed to Tomorrow Twitter Lifts Trump's Account Ban Scientists Find Evidence Of 10،000 Black Holes Surrounding The Center Of The Milky Way Galaxy Greenhouse In Antarctica Able To Grow Vegetables Without Soil Or Sunlight Moving Over China: U.S. Is Again Home to World's Speediest Supercomputer Technology The 10 most expensive cars in the world Technology Top 10 fastest cars in the world Technology Lasers Could Make Computers 1 Million Times Faster Technology Smart technology taking control of our lives Videos & Features Story behind Trending Jessica Radcliffe Death Video News Israeli-Linked Hadassah Clinic in Moscow Treats Wounded Iranian IRGC Fighters Arts & Culture "Jurassic World Rebirth" Gets Streaming Date News China Launches Largest Ever Aircraft Carrier News Ayat Khaddoura's Final Video Captures Bombardment of Beit Lahia Business Egyptian Pound Undervalued by 30%, Says Goldman Sachs Videos & Features Tragedy Overshadows MC Alger Championship Celebration: One Fan Dead, 11 Injured After Stadium Fall Arts & Culture South Korean Actress Kang Seo-ha Dies at 31 after Cancer Battle Lifestyle Get to Know 2025 Eid Al Adha Prayer Times in Egypt News The Jessica Radcliffe Orca Attack? 100% Fake and AI-Generated
Mid East Info
3 days ago
- Mid East Info
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated with a 16% lower rate of all-cause death compared to Trulicity, suggesting more comprehensive health benefits Results from the largest and longest Mounjaro trial to date reaffirm its established safety and tolerability profile Abu Dhabi, United Arab Emirates. August, 2025: Eli Lilly and Company (NYSE: LLY) today announced topline results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase 3 cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, was compared to Trulicity (dulaglutide), a GLP-1 receptor agonist that showed a definitive cardiovascular benefit in the REWIND study. In SURPASS-CVOT, Mounjaro achieved the primary objective by demonstrating a non-inferior rate of major adverse cardiovascular events (MACE-3), including cardiovascular death, heart attack or stroke vs. Trulicity. In addition, while not controlled for multiplicity-adjusted type-1 error, Mounjaro showed improvements on key measures of A1C, weight, renal function and all-cause mortality. The trial, which enrolled more than 13,000 participants across 30 countries and lasted more than four and a half years, is the largest and longest study of tirzepatide to date. 'Cardiovascular disease remains the leading cause of death among people living with type 2 diabetes,' said Kenneth Custer, Ph.D., executive vice president and president, Lilly Cardiometabolic Health. 'The SURPASS-CVOT results show that Mounjaro preserved the cardioprotective benefit of Trulicity, a GLP-1 receptor agonist, while providing additional benefits, including greater kidney protection and a reduced overall risk of death. These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes and cardiovascular disease.' In the trial, the risk of cardiovascular death, heart attack, or stroke was 8% lower for Mounjaro vs. Trulicity (hazard ratio: 0.92; 95.3% CI: 0.83 to 1.01), meeting the prespecified criteria for non-inferiority (upper limit of 95.3% CI of the hazard ratio < 1.05).1,2 Mounjaro showed consistent results across all three components of the MACE-3 composite endpoint. The rate of all-cause mortality was 16% lower for Mounjaro vs. Trulicity (hazard ratio: 0.84; 95.0% CI: 0.75 to 0.94).1,3 A pre-specified indirect comparison analysis of matched patient-level data from the REWIND and SURPASS-CVOT studies found that Mounjaro reduced the risk of MACE-3 by 28% (hazard ratio: 0.72; 95.0% CI: 0.55 to 0.94) and all-cause mortality by 39% (hazard ratio: 0.61; 95.0% CI: 0.45 to 0.82) compared to a putative placebo.3,4 In another key pre-specified analysis of participants with high or very-high risk of chronic kidney disease, Mounjaro slowed eGFR decline by 3.54 mL/min/1.73 m2 at 36 months vs. Trulicity (95.0% CI: 2.57 to 4.50).3,5,6 In the trial, Mounjaro also led to greater improvements in A1C, weight and cardiovascular biomarkers, including lipids and systolic blood pressure, compared to Trulicity.3 The safety and tolerability of Mounjaro and Trulicity were generally consistent with their established profiles. The most commonly reported adverse events in SURPASS-CVOT for both Mounjaro and Trulicity were gastrointestinal-related, generally mild-to-moderate in severity, and mostly resolved after dose escalation was complete. During the trial, 13.3% of participants taking Mounjaro discontinued treatment due to adverse events, compared to 10.2% of participants taking Trulicity.7 Detailed results for SURPASS-CVOT will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 in September and published in a peer-reviewed journal. Lilly plans to submit these data to global regulatory authorities by the end of this year. About SURPASS-CVOT: SURPASS-CVOT Cardiovascular Outcomes Trial; NCT04255433 was an event-driven, randomized, double-blind, parallel group Phase 3 trial evaluating the efficacy and safety of Mounjaro (tirzepatide) compared with Trulicity (dulaglutide) in adults with type 2 diabetes and established atherosclerotic cardiovascular disease, which lasted approximately five years (with a median follow-up of four years). In the trial, 13,299 participants were randomized 1:1 across 640 sites in 30 countries to receive the maximum tolerated dose (MTD) of Mounjaro (5 mg, 10 mg or 15 mg) or Trulicity (1.5 mg) administered subcutaneously once weekly. The primary objective of the trial was to demonstrate that Mounjaro provided a non-inferior reduction in the risk of major adverse cardiovascular events (MACE-3)—a composite of cardiovascular death, heart attack or stroke—compared to Trulicity. SURPASS-CVOT utilized MTD of 5 mg, 10 mg or 15 mg once weekly. The starting dose of 2.5 mg Mounjaro was increased by 2.5 mg every four weeks until MTD was achieved. Participants who tolerated 15 mg continued on 15 mg as their MTD. Participants who tolerated 10 mg but did not tolerate 15 mg continued on 10 mg as their MTD, and participants who tolerated 5 mg but did not tolerate 10 mg continued on 5 mg as their MTD. About REWIND 2019: REWIND NCT01394952 was a multicenter, randomized, double-blind, placebo-controlled trial, published in 2019, designed to assess the effect of Trulicity (1.5 mg) compared to placebo in adults with type 2 diabetes with and without established cardiovascular disease. The primary cardiovascular outcome was the first occurrence of MACE-3. Secondary outcomes include each component of the primary composite cardiovascular outcome, a composite clinical microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. In the trial, 9,901 participants from 24 countries had a mean duration of diabetes of 10.5 years and a median baseline A1C of 7.2%. About Lilly: Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Mid East Info
10-08-2025
- Mid East Info
Kilow launches Saudi Arabia's first integrated health marketplace for weight loss - Middle East Business News and Information
Kilow, Saudi Arabia's leading digital health and weight loss platform, is proud to announce the official launch of Kilow Marketplace: a first-of-its-kind platform that brings together medical tools, lab testing, nutritional supplements, medications, and fitness essentials – all in one place to support users across every stage of their wellness journey. Kilow Marketplace marks a strategic milestone in Kilow's vision to provide a medically guided and fully integrated ecosystem for healthy, sustainable weight loss, especially for users on GLP-1 treatments such as Ozempic or Mounjaro. 'We're not just offering products, we're building a smarter, more holistic experience around health. The marketplace connects users directly with the resources they need to succeed,' said Fahad Al Essa, Founder and CEO of Kilow. Marketplace Highlights: Initial partnerships with Bioniq and a growing list of certified labs and healthy nutrition providers. Organized experience: Medications, Labs, Supplements, Fitness Gear. Fully integrated with the Kilow app and user flow. Opportunities for local suppliers to directly reach high-intent health consumers. Kilow invites investors, health brands, and suppliers to join the platform and be part of transforming the health landscape in Saudi Arabia.
